Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18300431 | 1.00 | MAPT (0.32) | MAPTGAAKMT2AL3MBTL1F10 | |
| SCHEMBL14471373 | 0.83 | GAA (0.36) | MAPTGAAL3MBTL1RAB9ANPC1 | |
| SCHEMBL18300262 | 0.80 | MAPT (0.36) | MAPTGAAKMT2AL3MBTL1F10 | |
| SCHEMBL18300263 | 0.80 | MAPT (0.36) | MAPTGAAKMT2AL3MBTL1F10 | |
| SCHEMBL18300661 | 0.79 | F10 (0.37) | MAPTGAAKMT2AL3MBTL1F10 | |
| SCHEMBL18300660 | 0.79 | F10 (0.37) | MAPTGAAKMT2AL3MBTL1F10 | |
| SCHEMBL29413990 | 0.79 | NNMT (0.46) | L3MBTL1NNMT | |
| SCHEMBL15299575 | 0.78 | MAPK1 (0.50) | MAPTKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL16688436 | 0.77 | HDAC3 (0.38) | MAPTGAAKMT2AL3MBTL1RAB9A | |
| SCHEMBL15285101 | 0.74 | P4HA1 (0.46) | MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016201052-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | KLKB1, KLK1, KLK2 | MAPT 2685/4885GAA 1733/4885KMT2A 1323/4885 |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | MAPT 2685/4885GAA 1733/4885KMT2A 1323/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | MAPT 2685/4885GAA 1733/4885KMT2A 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.